Dr. Agarwal on Adverse Effects With Belzutifan and Mitigation Strategies in RCC

Video

In Partnership With:

Neeraj Agarwal, MD, discusses the adverse effects associated with belzutifan in patients with renal cell carcinoma.

Neeraj Agarwal, MD, professor of medicine, Presidential Endowed Chair of Cancer Research, director, Genitourinary Oncology Program and the Center of Investigational Therapeutics, Huntsman Cancer Institute, University of Utah, discusses the adverse effects (AEs) associated with belzutifan (MK-6482) in patients with renal cell carcinoma (RCC).

Unique AEs associated with belzutifan, that set this agent apart from VEGF TKIs, include anemia, fatigue, and hypoxia, according to Agarwal. These AEs are all related and may be easier to manage than other treatment-related AEs, Agarwal says. In fact, the AEs associated with belzutifan may be more favorable to patients with RCC who have previously been treated with VEGF TKIs and have experienced AEs such as hand-foot syndrome or a change in taste, Agarwal adds.

In terms of mitigation, dose reduction or blood transfusion can often correct anemia. Moreover, although hypoxia must be monitored, it should be manageable with either dose reduction or oxygen supplementation, Agarwal concludes.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,